Cardozo L
Department of Urogynaecology, King's College Hospital, 8 Devonshre Place, London W1G 6HP, UK.
J Obstet Gynaecol. 2005 Aug;25(6):539-43. doi: 10.1080/01443610500227961.
Stress urinary incontinence (SUI) is a significant problem for millions of women, many of whom remain untreated for years, sometimes for life. One reason for this is the lack of effective pharmacologic therapy. The drugs used for urge incontinence have little or no effect on leakage occurring without detrusor contraction under conditions of increased intra-abdominal pressure. Recent studies suggest that extrinsic urethral sphincter closure may be controlled by enhancing neurotransmission in pudendal pathways. A new agent, duloxetine, which inhibits serotonin-norepinephrine re-uptake in these pathways, is now in clinical trials and appears to be the first effective pharmacologic therapy for SUI.
压力性尿失禁（SUI）对数百万女性来说是一个重大问题，其中许多人多年来甚至终生未得到治疗。原因之一是缺乏有效的药物治疗。用于急迫性尿失禁的药物对在腹内压增加情况下无逼尿肌收缩时发生的漏尿几乎没有效果。最近的研究表明，外在尿道括约肌的闭合可能通过增强阴部神经通路中的神经传递来控制。一种新的药物度洛西汀，可抑制这些通路中的5-羟色胺-去甲肾上腺素再摄取，目前正在进行临床试验，似乎是第一种治疗SUI的有效药物疗法。
